TCM
CBAY

Tradewinds Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Tradewinds Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35
Closed – – 521
2022
Q2 		$0 Hold
35
– – ﹤0.01% 831
2022
Q1 		$0 Buy
+35
New +$110 ﹤0.01% 862

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Tradewinds Capital Management's CBAY Position: Q3 2022 in Review

Tradewinds Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 35 shares.

Tradewinds Capital Management first reported a position in CBAY in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

  • Tradewinds Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 35 Cymabay Therapeutics shares in Q3 2022.
  • Tradewinds Capital Management first reported a position in Cymabay Therapeutics in Q1 2022 and held it in 2 quarters.
  • Tradewinds Capital Management's Cymabay Therapeutics position peaked at $0 in Q2 2022.
  • 100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Tradewinds Capital Management's 13F filing for Q3 2022, filed 18 Oct 2022.